Skip to main content

BioNTech SE

corporate_fare Company Profile

BioNTech SE

BNTX·NASDAQ·Life Sciences·CIK 0001776985

BioNTech SE is dedicated to improving global health through fundamental research and development of immunotherapies. The company was founded and incorporated on June 2, 2008, as Petersberg 91, V AG, a German stock corporation. Its name changed to BioNTech AG on December 11, 2008. On March 8, 2019, the company converted to a European stock corporation (Societas Europaea, or SE) under the laws of Germany and the European Union, becoming BioNTech SE. BioNTech SE completed its initial public offering in October 2019. American Depositary Shares (ADSs) representing its ordinary shares are listed on the Nasdaq Global Select Market under the symbol "BNTX". The company's principal executive offices are located at An der Goldgrube 12, D-55131 Mainz, Germany. Its telephone number is +49 6131-9084-0. The agent for service of process for SEC notices in the United States is c/o BioNTech US Inc., 40 Erie Street, Suite 110, Cambridge, Massachusetts 02139, with telephone number +1 (617) 337-4701.

BioNTech SE (NASDAQ:BNTX) is a publicly traded company in the Life Sciences sector. Wiseek monitors BNTX SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • CEO-affiliated entity files intent to sell $93.8M in BioNTech shares
  • BioNTech Appoints Kylie Jimenez as Chief People Officer to Management Board
  • BioNTech Outlines Robust Oncology Pipeline and Strategic Vision at J.P. Morgan Conference
  • BioNTech Outlines Catalyst-Rich 2026 with 7 Late-Stage Oncology Data Readouts and 15 Phase 3 Trials
  • BioNTech Completes Full Takeover of CureVac's Business Operations

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
€2.87B EUR
Net Income
-€1.14B EUR
Diluted EPS
-€4.70 EUR
Op. Cash Flow
€456M EUR
Free Cash Flow
€280.9M EUR
Gross Profit
€2.23B EUR
Operating Income
-€1.4B EUR
Cash & Equivalents
€7.68B EUR
Debt / Equity
0.00×
Net Margin
-39.6%
Shares Outstanding
251.33M sh
Source: 20-F · filed 2026-04-01 · accession 0001776985-26-000023

Insider Transactions

BNTX files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

$90.88 +0.34% today
52-week range · as of 2026-06-08 $79.52 – $124
Market cap
$22.9B
Volume
1.1M (1.1× avg)
3-mo avg 1.1M
Live data · 2026-06-14 06:17 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BNTX - Filings & News (Page 2)

BNTX
Feb 12, 2026, 8:17 AM EST
Filing Type: 144
Importance Score:
8
CEO-affiliated entity files intent to sell $93.8M in BioNTech shares
Price at Filing: $109.38
Real-time Price: $90.88 info
Change: -$18.50 (-17%) info
Market Cap: $22.896B info
Sentiment: Negative
View Wiseek Article
BNTX
Jan 28, 2026, 8:10 AM EST
Filing Type: 6-K
Importance Score:
7
BioNTech Appoints Kylie Jimenez as Chief People Officer to Management Board
Price at Filing: $118.81
Real-time Price: $90.88 info
Change: -$27.93 (-24%) info
Market Cap: $22.896B info
Sentiment: Positive
View Wiseek Article
BNTX
Jan 13, 2026, 6:18 PM EST
Filing Type: 6-K
Importance Score:
7
BioNTech Outlines Robust Oncology Pipeline and Strategic Vision at J.P. Morgan Conference
Price at Filing: $108.57
Real-time Price: $90.88 info
Change: -$17.69 (-16%) info
Market Cap: $22.896B info
Sentiment: Positive
View Wiseek Article
BNTX
Jan 12, 2026, 6:57 AM EST
Filing Type: 6-K
Importance Score:
8
BioNTech Outlines Catalyst-Rich 2026 with 7 Late-Stage Oncology Data Readouts and 15 Phase 3 Trials
Price at Filing: $99.38
Real-time Price: $90.88 info
Change: -$8.50 (-9%) info
Market Cap: $22.896B info
Sentiment: Positive
View Wiseek Article
BNTX
Jan 06, 2026, 6:05 AM EST
Filing Type: 6-K
Importance Score:
8
BioNTech Completes Full Takeover of CureVac's Business Operations
Price at Filing: $96.83
Real-time Price: $90.88 info
Change: -$5.95 (-6%) info
Market Cap: $22.896B info
Sentiment: Neutral
View Wiseek Article